CFM
TLX

Cornerstone Financial Management’s Telix Pharmaceuticals TLX Stock Holding History

Cornerstone Financial Management’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51
Closed -$382 – 1399
2025
Q4 		$382 Buy
+51
New +$491 ﹤0.01% 1227

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return

Cornerstone Financial Management's TLX Position: Q1 2026 in Review

Cornerstone Financial Management sold out of Telix Pharmaceuticals (TLX) in Q1 2026, closing a stake of 51 shares — an estimated $382 sold.

Cornerstone Financial Management first reported a position in TLX in Q4 2025 and held it in 1 quarter. The position peaked at $382 in Q4 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Cornerstone Financial Management reported no remaining Telix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cornerstone Financial Management sold 51 Telix Pharmaceuticals shares in Q1 2026, an estimated $382.
  • Cornerstone Financial Management first reported a position in Telix Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Cornerstone Financial Management's Telix Pharmaceuticals position peaked at $382 in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Cornerstone Financial Management's 13F filing for Q1 2026, filed 8 May 2026.